Control | A+/T− | A+/T+ | |
---|---|---|---|
Participants with concurrent Aβ PET, tau PET, and MRI at baseline (n = 487) | |||
A/T/N, n (%) | 162 (33.3) | 143 (29.4) | 182 (37.4) |
Diagnosis, CU:CI | 162:0 | 93:50 | 48:134 |
Females, n (%) | 102 (63.0) | 66 (46.1)a | 98 (53.8) |
Age, years, median (IQR, range) | 69.1 (7.7, 55.3–85.0) | 74.8 (11.2, 56.6–92.2)a | 75.7 (10.9, 55.7–94.0)b |
Age < 65, n (%) | 21 (13.0) | 13 (9.1) | 16 (8.8) |
Age < 72.7, n (%) | 116 (71.6) | 60 (42.0)a | 67 (36.8)b |
Education, years, median (IQR, range) | 17 (2, 11–20) | 17 (3, 12–20) | 16 (4, 12–20)b,c |
APOE-ε4, n (%) | 39 (24.7) | 65 (47.8)a | 112 (65.9)b,c |
APOE-ε2, n (%) | 19 (12.0) | 5 (3.7)a | 4 (2.4)b |
KL-VShet+, n (%) | 43 (30.5) | 35 (29.9) | 24 (19.4) |
Aβ PET Centiloids, median (IQR, range) | 7.1 (11.2, −17.3–22.4) | 47.2 (46.2, 20.7–152.3)a | 87.0 (55.8, 16.4–253.4)b,c |
Participants with ≥2 Aβ PET scans (n = 199) | |||
A/T/N, n (%) | 80 (40.2) | 58 (29.1) | 61 (30.7) |
Diagnosis, CU:CI | 80:0 | 42:16 | 27:34 |
Females, n (%) | 53 (66.3) | 24 (41.4)a | 38 (62.3) |
Age, years, median (IQR, range) | 69.2 (8.7, 58.4–83.7) | 75.5 (8.9, 62.2–91.5)a | 76.6 (10.7, 56.3–90.4)b |
Age < 65, n (%) | 8 (10.0) | 3 (5.2) | 5 (8.2) |
Age < 72.7, n (%) | 54 (67.5) | 20 (34.5)a | 21 (34.4)b |
Education, years, median (IQR, range) | 17.5 (2, 11–20) | 17.0 (4, 12–20) | 16.0 (4, 12–20)b,c |
APOE-ε4, n (%) | 24 (30.4) | 31 (53.4)a | 36 (59.0)b |
APOE-ε2, n (%) | 9 (11.4) | 1 (1.7) | 3 (4.9) |
KL-VShet+, n (%) | 21 (28.4) | 13 (23.2) | 14 (23.7) |
FU visits, median (IQR, range) | 2 (0, 2–3) | 2 (0, 2–3) | 2 (0, 2–) |
Duration of FU, years, median (IQR, range) | 2.1 (0.4, 1.3–4.2) | 2.0 (0.2, 0.8–3.8) | 2.1 (0.2, 1.0–3.7) |
Participants with ≥2 tau PET scans (n = 192) | |||
A/T/N, n (%) | 37 (19.3) | 71 (37.0) | 84 (43.8) |
Diagnosis, CU:CI | 37:0 | 46:25 | 27:57 |
Females, n (%) | 23 (62.2) | 27 (38.0)a | 52 (61.9)c |
Age, years, median (IQR, range) | 69.2 (9.3, 62.8–82.7) | 73.9 (9.7, 58.2–92.2)a | 75.8 (10.0, 55.7–89.6)b |
Age < 65, n (%) | 6 (16.2) | 5 (7.0) | 9 (10.7) |
Age < 72.7, n (%) | 26 (70.3) | 30 (42.3)a | 32 (38.1)b |
Education, years, median (IQR, range) | 16 (3, 12–20) | 17 (4, 12–20) | 16 (4, 12–20)c |
APOE-ε4, n (%) | 12 (32.4) | 39 (56.5)a | 56 (70.0)b |
APOE-ε2, n (%) | 4 (10.8) | 2 (2.9) | 2 (2.5) |
KL-VShet+, n (%) | 14 (41.2) | 19 (31.1) | 14 (20.9) |
FU visits, median (IQR, range) | 2 (1, 2–5) | 2 (1, –4) | 2 (1, 2–4) |
Duration of FU, years, median (IQR, range) | 2.0 (1.1, 0.9–3.7) | 1.5 (1.0, 0.8–3.6) | 1.5 (1.0, 0.8–4.0) |